This article was originally published in The Gray Sheet
Executive SummarySeventh-generation AVE coronary stent system receives FDA approval, firm announces April 5. The S7 boasts shorter element lengths (1 mm) and a smaller cross-sectional area, providing additional flexibility to track through complex anatomy and reach difficult lesions that its S670 predecessor cannot. Device incorporates patented Discrete technology and offers perfusion capabilities at an average rate of 2 cc/minute at nominal pressure. Shipments began immediately to interventional cardiologists in the U.S. and abroad
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.